Benefits and Challenges of Diabetes Technology Use in Older Adults

With successful aging of adults with type 1 diabetes, there is an increased opportunity to use technology for diabetes management. Technology can ease the burden of self-care and provide a sense of security. However, age-related cognitive and physical decline can make technology use difficult. Guidelines using technology in the aging population are urgently needed, along with educational material for the clinicians and caregivers. In this article, we review the evidence supporting the use of diabetes-related technologies in the older population and discuss recommendations based on current data and the authors ’ clinical knowledge and experience.
Source: Endocrinology and Metabolism Clinics of North America - Category: Endocrinology Authors: Source Type: research

Related Links:

Glycemic control in type 1 diabetes mellitus (T1DM) remains a challenge for many, despite the availability of modern diabetes technology. While technologies have proven glycemic benefits and may reduce excess mortality in some populations, both mortality a...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Conclusions: Our estimated rates of prevalence of GP in T1DM and T2DM indicate that GP is not a common clinical complication in these populations. Majority of EMRs that indicated a diagnosis of GP did not include any documentation of definitive diagnostic testing (EGD and/or GES).
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: ALIMENTARY TRACT: Original Articles Source Type: research
ConclusionsCirculating TNFR-1 and TNFR-2 are independently associated with higher risk of renal disease progression, CVD events, and mortality in patients with diabetes and might contribute to the clinical risk assessment in the future.
Source: Endocrine - Category: Endocrinology Source Type: research
AbstractPhysiological plasticity enables homeostasis to be maintained in biological systems, but when such allostasis fails, then disease can develop. In a new population-based study by Rolandsson et al (https://doi.org/10.1007/s00125-019-05016-3), autoimmunity, defined by an immunogenotype, predicted adult-onset non-insulin requiring diabetes. Type 1 diabetes is no longer viewed as a disease confined to children, with a significant proportion, maybe the majority, presenting in adulthood. Such cases masquerade as type 2 diabetes and their identification has clinical utility. Nevertheless, in this study, autoimmunity had a ...
Source: Diabetologia - Category: Endocrinology Source Type: research
ConclusionsFlash glucose monitoring may be an acceptable self-management tool to increase monitoring frequency in adolescents and young adults with type 1 diabetes and high-risk glycemic control, with the potential to improve long-term glycemic control. Initial support efforts should focus on practical strategies to prolong sensor wear and motivate frequent scanning as well as education on interpreting glucose data and making informed treatment decisions to maximize the benefits of this technology.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
AbstractSodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing the incidence of hypoglycaemia. However, the appropriate use of SGLT2 inhibitor therapies within clinical practise to treat people with T1DM remains unclear. In this article we have used consensus expert opinion alongside the available evidence, product indication and most recent clinical guidance to provide support for t...
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Researchers believe they may help restore normal immune function in adults with type 1 disease with injections of stem cells, enabling the pancreas to produce insulin.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
W.L. Gore &Associates is setting its sights on helping to improve insulin therapy in patients with type 1 diabetes. To do this the Flagstaff, AZ-based company is investing in PhysioLogic Devices, a startup developing an implantable intraperitoneal insulin delivery system. The investment is set to provide supplemental funding to allow Elkton, MD-based PhysioLogic to reduce key challenges associated with implantable micropumps and actuators and enable the startup's development goals for the upcoming years. An essential part of the system that PhysioLogic is developing is an implanted catheter for intraperitoneal insulin ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
FRIDAY, Dec. 6, 2019 -- Preterm birth is associated with an increased risk for type 1 and type 2 diabetes from childhood into early and middle adulthood, according to a study published online Dec. 3 in Diabetologia. Casey Crump, M.D., from the Icahn...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
(Medical University of South Carolina) MUSC researchers launch the first NIH-funded clinical trial in the United States using umbilical cord derived mesenchymal stem cells for the treatment of patients with new onset type 1 diabetes.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Diabetes | Diabetes Type 1 | Education | Endocrinology